The estimated Net Worth of Gary Ingenito is at least $4.16 million dollars as of 9 August 2024. Gary Ingenito owns over 100,000 units of Catalyst Pharmaceuticals Inc stock worth over $2,946,069 and over the last 9 years he sold CPRX stock worth over $0. In addition, he makes $1,213,670 as Chief Medical Officer and Head of Regulatory Affairs at Catalyst Pharmaceuticals Inc.
Gary has made over 14 trades of the Catalyst Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of CPRX stock worth $401,000 on 9 August 2024.
The largest trade he's ever made was exercising 150,000 units of Catalyst Pharmaceuticals Inc stock on 21 June 2022 worth over $619,500. On average, Gary trades about 36,385 units every 66 days since 2015. As of 9 August 2024 he still owns at least 151,391 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Gary Ingenito stock trades at the bottom of the page.
Dr. Gary Ingenito, M.D., Ph.D., is Chief Medical Officer of Catalyst Pharmaceuticals, Inc. Prior to joining Catalyst, Dr. Ingenito spent more than 25 years in the field of pharmaceutical development; including drugs, biologics, and combination products. During this time, Dr. Ingenito has held executive responsibilities for clinical research, regulatory, drug safety, and medical affairs at pharmaceutical companies and contract research organizations. Dr. Ingenito initially joined Sandoz Pharmaceuticals in the neuroendocrine group and progressed to become head of medical affairs. He spent 8 years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular, and central nervous system products. Dr. Ingenito has also held positions at Corning-Besselaar, SFBC International, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and, most recently at Boehringer-Ingelheim Pharmaceuticals, where he served as head of regulatory affairs North America for biosimilars. After obtaining his bachelor of arts degree from The Johns Hopkins University, Dr. Ingenito earned his medical degree at Jefferson Medical College, and a Ph.D. in philosophy from Thomas Jefferson University. He completed a post-graduate residency in neurology at the University of Miami, Jackson Memorial Hospital.
As the Chief Medical Officer and Head of Regulatory Affairs of Catalyst Pharmaceuticals Inc, the total compensation of Gary Ingenito at Catalyst Pharmaceuticals Inc is $1,213,670. There are 2 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of $3,371,560.
Gary Ingenito is 64, he's been the Chief Medical Officer and Head of Regulatory Affairs of Catalyst Pharmaceuticals Inc since 2016. There are 6 older and 10 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
Gary's mailing address filed with the SEC is 355 Alhambra Cir #1250, Coral Gables, FL 33134, USA.
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany et Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: